Panaxia Labs Israel Ltd. announced preliminary revenue outlook for the third quarter of 2020. The company estimates its unaudited consolidated revenues in the third quarter of 2020 will be at least 16.3 million. The revenues of the third quarter reflect an increase of more than 10%, driven by the larger number of patients and the scope of products manufactured by the company. the company projects that its revenues for the first nine months of 2020 will amount to at least 43.2 million.